-
Product Insights
NewMalaria – Drugs In Development, 2024
Empower your strategies with our Malaria – Drugs In Development, 2024 report and make more profitable business decisions. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea, and vomiting. Treatment includes anti-malarial medicines....
-
Product Insights
NewTuberculosis – Drugs In Development, 2024
Empower your strategies with our Tuberculosis – Drugs In Development, 2024 report and make more profitable business decisions. Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus; fatigue; shortness of breath; weight...
-
Product Insights
NewDyskinesia – Drugs In Development, 2024
Empower your strategies with our Dyskinesia – Drugs In Development, 2024 report and make more profitable business decisions. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing, and tongue thrusting. The disease can be controlled by healthy life style and medication. The Dyskinesia drugs in development market research report provide comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADS-024 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADS-024 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details: ART-24 (ADS-024) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Influenza [Strain A/H7N9] Vaccine in Influenza A Virus, H7N9 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Influenza [Strain A/H7N9] Vaccine in Influenza A Virus, H7N9 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Influenza [Strain A/H7N9] Vaccine in Influenza...
-
Company Profile
EpiVax Inc – Company Profile
EpiVax Inc (EpiVax) develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T cells. It is an immune-modulation power tool that is being developed for auto-immune, auto-inflammatory and allergic conditions. EpiVax’ service portfolio includes immune engineering, immunogenicity screening, vaccine design, and redesign. The company also provides lab services such as in vivo, in...
Add to Basket -
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...
-
Product Insights
Influenza A Virus, H7N9 Subtype Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Influenza A Virus, H7N9 Subtype Infections Pipeline Drugs Market Report Overview Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia, and general malaise. Treatment includes antiviral drugs. The Influenza A Virus, H7N9 Subtype Infections pipeline drugs market research report provides comprehensive information on the Influenza A Virus,...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Cytotoxic T-cell based cancer immunotherapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Cytotoxic T-cell based cancer immunotherapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...